|
|
Volumn 345, Issue 6198, 2014, Pages 718-719
|
|
Debate erupts on 'repurposed' drugs for ebola
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
ATORVASTATIN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
VIRUS VACCINE;
ANTIVIRUS AGENT;
IMMUNOSUPPRESSIVE AGENT;
DISEASE PREVALENCE;
DRUG;
HEALTH RISK;
MORTALITY;
POPULATION OUTBREAK;
PRIMATE;
VIRAL DISEASE;
CELL CULTURE;
EBOLA HEMORRHAGIC FEVER;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNE RESPONSE;
MEDICAL RESEARCH;
PERCEPTION;
PRIORITY JOURNAL;
PUBLIC HEALTH;
SCIENTIST;
SEPSIS;
SHORT SURVEY;
WORLD HEALTH ORGANIZATION;
DRUG APPROVAL;
DRUG REPOSITIONING;
ETHICS;
IMMUNOLOGY;
MEDICAL ETHICS;
NOTE;
WEST AFRICA;
ANTIVIRAL AGENTS;
DRUG APPROVAL;
DRUG REPOSITIONING;
ETHICS, CLINICAL;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
|
|
EID: 84906079218
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.345.6198.718 Document Type: Short Survey |
|
Times cited : (24)
|
|
References (0)
|
